Benzbromarone withdrawn from the European market: Another case of "absence of evidence is evidence of absence"? [1]

Clinical and Experimental Rheumatology

Volumn 22, Issue 5, 2004, Pages 651-

  Jansen, T L Th A ^a   Reinders, M K ^b   Van Roon, E N ^c   Brouwers, J R B J ^c  

^a MEDICAL CENTER LEEUWARDEN   (Netherlands)

^b Hospital Pharmacist in Training

^c Department of Clinical Pharmacology ^*

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; AZATHIOPRINE; BENZBROMARONE; PROBENECID; SULFINPYRAZONE; URIC ACID; URICOSURIC AGENT;

DRUG APPROVAL; DRUG CONTROL; DRUG ERUPTION; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG MANUFACTURE; DRUG MARKETING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; EUROPE; FACE EDEMA; FEVER; GOUT; HUMAN; LETTER; LIVER FAILURE; MONOTHERAPY; OUTCOMES RESEARCH; PATHOPHYSIOLOGY; PRESCRIPTION; PRIORITY JOURNAL; TONGUE DISEASE; URIC ACID BLOOD LEVEL; URIC ACID URINE LEVEL;

BENZBROMARONE; DRUG APPROVAL; EUROPE; GOUT; HUMANS; URICOSURIC AGENTS;

EID: 4644372318     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (7)

1. DAY RO, MINERS JO, BIRKETT DJ et al.: Allopurinol dosage selection: relationships between dose and plasma oxypurinol and urate concentrations and urinary urate excretion. Br J Clin Pharmacol 1988; 26: 423-8.
2. FAM AG: Hyperuricemia and gout. In RAKEL RE (Ed.): Conn's Current Therapy, 51st ed., Philadelphia, W.B. Saunders Co., 1999; 561-6.
3. LI-YU J, CLAYBURNE G, SIECK M et al.: Treatment of chronic gout. Can we determine when urate stores are depleted enough to prevent attacks of gout ? J Rheumatol 2001; 28: 577-80.
4. ALLEN DJ, MILOSOVICH G, MATTACKS AM: Inhibition of monosodium urate crystal growth. Arthritis Rheum 1965; 8: 1123.
5. PEREZ-RUIZ E, ALONSO-RUIZ, CALABOZO M et al.: Efficacy of allopurinol and benzbromarone for the control of hyperuricemia. A pathogenic approach to the treatment of primary chronic gout. Ann Rheum Dis 1998; 57: 545-9.
6. van de KLAUW MM, HOUTMAN PM, STRICKER BH et al.: Hepatic injury caused by benzbromarone. J Hepatol 1994; 20: 276-9.
7. LOCUSON CW, WAHLSTROM JL, ROCK DA et al.: A new class of CYP2C9 inhibitors: probing 2C9 specificity with high affinity benzbromarone derivatives. Drug Metab Dispos 2003; 31: 967-71.